SCHEMBL5540895

SCHEMBL5540895

Fc1cc(O[CH]c2ccccc2)cc(F)c1F

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EGFR P00533 1/20 0.39
NFE2L2 Q16236 7/20 0.35
TUBB1 Q9H4B7 2/20 0.33
TRPA1 O75762 1/20 0.31
RELA Q04206 1/20 0.31
ALDH1A1 P00352 2/20 0.30
TSHR P16473 1/20 0.30
KDM4E B2RXH2 1/20 0.30
MEN1 O00255 1/20 0.30
USP2 O75604 1/20 0.30
TP53 P04637 1/20 0.30
CYP3A4 P08684 1/20 0.30
MAPT P10636 1/20 0.30
HPGD P15428 1/20 0.30
KMT2A Q03164 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
TRPV1 Q8NER1 1/20 0.30
HSD17B10 Q99714 1/20 0.30
MAOB P27338 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5537200 0.78 PPARG (0.44) NFE2L2TRPA1ALDH1A1CYP3A4MAPT
SCHEMBL536918 0.75 TSHR (0.43) NFE2L2TRPA1RELAALDH1A1TSHR
SCHEMBL4179961 0.75 NFE2L2 (0.52) EGFRNFE2L2TRPA1RELAALDH1A1
SCHEMBL5537611 0.74 ACHE (0.38) NFE2L2TRPA1RELATSHRKMT2A
SCHEMBL5540271 0.73 ALDH1A1 (0.50) EGFRTUBB1TRPA1ALDH1A1KDM4E
SCHEMBL5540388 0.73 NPSR1 (0.41) TRPA1RELAALDH1A1TSHRKDM4E
SCHEMBL5545196 0.73 PIM1 (0.38) MEN1KMT2A
SCHEMBL5543869 0.73 IDO1 (0.44) NFE2L2ALDH1A1TSHRMEN1MAPT
SCHEMBL6001493 0.71 NFE2L2 (0.42) NFE2L2TRPA1ALDH1A1MEN1MAPT
SCHEMBL28821313 0.69 NFE2L2 (0.41) EGFRNFE2L2RELATSHRCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 EGFR 3049/4885NFE2L2 846/4885TUBB1 392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.